GDC-0623 Size:Solid 10 mg Smiles: CN1CCC[C@@H]1CCO[C@](C)(C1C=CC=CC=1)C1C=CC(Cl)=CC=1

Smiles: CN1CCC[C@@H]1CCO[C@](C)(C1C=CC=CC=1)C1C=CC(Cl)=CC=1

and AKT in MDA-MB-453 cells

5-3(6)1-2-4(7)8/h2-9

InChi: InChI=1S/C21H19Cl3N2O3/c1-3-20(27)25-6-8-26(9-7-25)21(28)16-11-15(18(24)12-19(16)29-2)14-10-13(22)4-5-17(14)23/h3-5

68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13

GDC-0623 Size:Solid 10 mg Smiles: CN1CCC[C@@H]1CCO[C@](C)(C1C=CC=CC=1)C1C=CC(Cl)=CC=1GDC 0623, also known as G 868, is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC 0623 specifically inhibits mitogen activated protein kinase kinase (MEK or MAP ERK kinase), resulting in inhibition of growth factor mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS RAF MEK ERK signaling pathway that regulates cell growth; constitutive activation of this pathway